Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.37 |
| ▸ | RAB9A | P51151 | 11/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369110 | 0.82 | ALDH1A1 (0.47) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6369028 | 0.78 | NPC1 (0.43) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL4181845 | 0.78 | MAOB (0.38) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7431136 | 0.71 | MRGPRX1 (0.48) | ALDH1A1MAPK1 | |
| SCHEMBL7397888 | 0.71 | MRGPRX1 (0.43) | ALDH1A1MAPK1 | |
| SCHEMBL6373837 | 0.70 | KMT2A (0.41) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7334464 | 0.69 | NOTUM (0.35) | — | |
| SCHEMBL13385009 | 0.69 | NPC1 (0.41) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6374647 | 0.69 | SMN1; SMN2 (0.50) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6369200 | 0.69 | PARP1 (0.44) | NPC1RAB9AKMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | GAMMILL RONALD B (US) | 2005-01-27 | — | — | US | disclosed |
| US-6821977-B2 | SUBSTITUTED 1H-(INDOLE-2- CARBOXAMIDES AND 6H-THIENO(2,3-B)PYRROLE-5-CARBOXAMIDES USEFUL FOR INHIBITING GLYCOGEN PHOSPHORYLASE IN A MAMMAL | PFIZER, INC. | 2004-11-23 | — | — | US | disclosed |
| US-20030199553-A1 | Antidiabetic agents | GAMMILL RONALD B (US) | 2003-10-23 | — | — | US | disclosed |
| EP-1340500-A1 | Antidiabetic agents | Pfizer Products Inc. (US) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199553-A1 | Antidiabetic agents | GPR119, IRS1, INSR | NPC1 27/4885RAB9A 735/4885KMT2A 4151/4885 |
| US-20050020661-A1 | Substituted 1H-indole-2- carboxamides and 6H-thieno(2,3-b)pyrrole-5-carboxamides useful for inhibiting glycogen phosphorylase in a mammal | PYGM, PYGL, IRS1 | NPC1 1066/4885RAB9A 2493/4885KMT2A 2347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.